Six Upcoming Presentations at the Annual Meetings of the American Society of Gene and Cell Therapy (ASGCT) and of the International Society for Extracellular Vesicles (ISEV)
OXFORD, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) — Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, will present data at two upcoming international conferences: the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, May 16-20, 2023, in Los Angeles, and the International Society for Extracellular Vesicles (ISEV) Annual Meeting, May 17-21, 2023, in Seattle. The six oral presentations and posters highlight the progress made in leveraging the versatility of the Company’s DeliverEX® exosome platform to deliver a wide range of genetic medicines ranging from genome editors, RNAi and mRNA as well as presenting on other exosome-related advances.
“We have developed the leading exosome engineering platform that is orders of magnitude better than the prior state of the art and is capable of delivering a wide range of protein and RNA drugs,” said Antonin de Fougerolles, Ph.D., Chief Executive Officer of Evox Therapeutics. “We believe that exosomes are uniquely suited for delivery of many of these payloads, particularly delivery of gene therapy and genome editors to tissues such as the central nervous system (CNS) where current options are extremely limited. The quick efficient uptake of exosomes into cells and rapid clearance from circulation along with their outstanding safety profile make them ideally suited for these applications”.
American Society of Gene and Cell Therapy (ASGCT) presentations and posters
International Society for Extracellular Vesicles (ISEV) presentations and posters
About Evox Therapeutics
Evox Therapeutics is a privately held, Oxford-based biotechnology company that is a leader in harnessing and engineering the natural delivery capabilities of extracellular vesicles (EVs), known as exosomes, to develop an entirely new class of therapeutics for the treatment of severe rare diseases. Evox uses its proprietary DeliverEX® technology to engineer exosomes to facilitate drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of genetic medicines such as gene therapy, gene editing, and RNA therapeutics by enabling safe non-immunogenic repeated delivery to cells and tissues that are currently out of reach using other drug delivery technologies. Evox is backed by leading life sciences venture capital groups including Redmile and OrbiMed, and is supported by a comprehensive intellectual property portfolio.
For further information visit:
For enquiries, please contact:
U.S. Investors:
Burns McClellan
Investor.Relations@burnsmc.com
U.S. Media:
Burns McClellan
Media.Relations@burnsmc.com
Evox:
Dr. Antonin de Fougerolles, CEO
+44 (0) 1865 819140
For further information visit: www.evoxtherapeutics.com
The new proprietary cell line development platform combines a robust cell line, transposon technology with…
GRASS VALLEY, CA / ACCESSWIRE / June 4, 2024 / Applied Science, the worldwide leader…
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…
SEATTLE, June 4, 2024 /PRNewswire/ -- AffableBPM, a leader in AI-powered business process automation for…
Azenta has been Selected by the Crohn's & Colitis Foundation as its Sample Management Services…